The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014
| Jurisdiction | UK Non-devolved |
| Citation | SI 2014/3271 |
| Year | 2014 |
2014No. 3271
DANGEROUS DRUGS
The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014
10thDecember2014
At the Court at Buckingham Palace, the 10th day of December 2014
Present,
The Queen's Most Excellent Majesty in Council
In accordance with section 2(5) of the Misuse of Drugs Act 1971( 1) a draft of this Order has been laid before Parliament on the recommendation of the Advisory Council on the Misuse of Drugs and approved by a resolution of each House of Parliament.
Accordingly, Her Majesty, in exercise of the powers conferred upon Her by section 2(2) of that Act, is pleased, by and with the advice of Her Privy Council, to order as follows:
Citation and commencement
1. This Order may be cited as the Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014 and comes into force on the twenty-eighth day after the day on which it is made.
Amendments to the Misuse of Drugs Act 1971
2. The following amendments are made to Schedule 2 to the Misuse of Drugs Act 1971.
3. In paragraph 1(a) of Part 1 (which specifies the drugs which are subject to control under that Act as Class A drugs)-
(a) after "Trimeperidine" insert-"(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ALD-52).";
(b) after "4-Cyano-1-methyl-4-phenyl-piperidine" insert-"3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921);
(6aR,9R)R,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD) (6aR,9R)R,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD) (6aR,9R)R,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)." (c) after "N,N-Diethyltryptamine" insert-"2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl}methanone (LSZ).".
4. For paragraph 1(b) of Part 1, substitute-
"(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say-(i) by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl...To continue reading
Request your trial